Skip to main content
SpringerLink
Log in

Steroid Use in Crohn’s Disease

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The incidence and prevalence of Crohn’s disease are increasing, particularly in the Western world and Asia. Corticosteroids have been used for decades to treat active Crohn’s disease and remain the mainstay in the management of moderate-to-severe relapses in Crohn’s disease. The use of corticosteroids, despite their efficacy, may be associated with several drawbacks. This review article provides a comprehensive account of the role of corticosteroids in inducing remission in adult patients with Crohn’s disease, including aspects such as approaches to corticosteroid sparing and to minimize the risk of corticosteroid dependency, as well as the role of newer corticosteroids such as budesonide in reducing systemic adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn’s disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007;26:987–1003.

    Article  CAS  PubMed  Google Scholar 

  2. Hanauer SB, Sandborn W. Practice Parameters Committee of the American College of G. Management of Crohn’s disease in adults. Am J Gastroenterol. 2001;96:635–43.

    Article  CAS  PubMed  Google Scholar 

  3. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122:512–30.

    Article  PubMed  Google Scholar 

  4. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62.

    Article  CAS  PubMed  Google Scholar 

  5. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–57.

    Article  CAS  PubMed  Google Scholar 

  6. Hyams JS. Inflammatory bowel disease. Pediatrics Rev/Am Acad Pediatr. 2005;26:314–20.

    Article  Google Scholar 

  7. Hayashi R, Wada H, Ito K, et al. Effects of glucocorticoids on gene transcription. Eur J Pharmacol. 2004;500:51–62.

    Article  CAS  PubMed  Google Scholar 

  8. Yang YX, Lichtenstein GR. Corticosteroids in Crohn’s disease. Am J Gastroenterol. 2002;97:803–23.

    Article  CAS  PubMed  Google Scholar 

  9. Hyams JS. Diet and gastrointestinal disease. Curr Opin Pediatr. 2002;14:567–9.

    Article  PubMed  Google Scholar 

  10. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ. 1955;2:1041–8.

    Article  CAS  PubMed  Google Scholar 

  11. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis. 2010;4:63–101.

    Article  PubMed  Google Scholar 

  12. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;1:1067–70.

    Article  CAS  PubMed  Google Scholar 

  13. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35:360–2.

    Article  CAS  PubMed  Google Scholar 

  14. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.

    Article  CAS  PubMed  Google Scholar 

  15. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–66.

    CAS  PubMed  Google Scholar 

  16. Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319–30.

    Article  CAS  PubMed  Google Scholar 

  17. Papi C, Festa V, Leandro G, et al. Long-term outcome of Crohn’s disease following corticosteroid-induced remission. Am J Gastroenterol. 2007;102:814–9.

    Article  CAS  PubMed  Google Scholar 

  18. Franchimont DP, Louis E, Croes F, et al. Clinical pattern of corticosteroid dependent Crohn’s disease. Eur J Gastroenterol Hepatol. 1998;10:821–5.

    Article  CAS  PubMed  Google Scholar 

  19. Keenan GF. Management of complications of glucocorticoid therapy. Clin Chest Med. 1997;18:507–20.

    Article  CAS  PubMed  Google Scholar 

  20. Carter MJ, Lobo AJ, Travis SP, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5):V1–16.

    Article  PubMed  Google Scholar 

  21. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77:847–69.

    CAS  PubMed  Google Scholar 

  22. Singleton JW, Law DH, Kelley ML Jr, et al. National Cooperative Crohn’s Disease Study: adverse reactions to study drugs. Gastroenterology. 1979;77:870–82.

    CAS  PubMed  Google Scholar 

  23. Schoon EJ, van Nunen AB, Wouters RS, et al. Osteopenia and osteoporosis in Crohn’s disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl. 2000;43–7.

  24. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;125:961–8.

    Article  CAS  PubMed  Google Scholar 

  25. van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM: Monthly J Assoc Physicians. 2000;93:105–11.

    Article  Google Scholar 

  26. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940–87.

    Article  CAS  PubMed  Google Scholar 

  27. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:935–9.

    Article  PubMed  Google Scholar 

  28. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795–841.

    Article  PubMed  Google Scholar 

  29. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–32.

    Article  CAS  PubMed  Google Scholar 

  30. Akerkar GA, Peppercorn MA, Hamel MB, et al. Corticosteroid-associated complications in elderly Crohn’s disease patients. Am J Gastroenterol. 1997;92:461–4.

    CAS  PubMed  Google Scholar 

  31. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–30.

    Article  CAS  PubMed  Google Scholar 

  32. Brignola C, Campieri M, Farruggia P, et al. The possible utility of steroids in the prevention of relapses of Crohn’s disease in remission: a preliminary study. J Clin Gastroenterol. 1988;10:631–4.

    Article  CAS  PubMed  Google Scholar 

  33. Scholmerich JJH, Hartmann F, Döpfer H. The German 5-ASA Study. Can J Gastroenterol. 1990;4:446–51.

    Google Scholar 

  34. Benchimol EI, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009:CD002913.

  35. Gross V, Andus T, Fischbach W, et al. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn’s ileocolitis: a multicenter randomized double-blind study. German 5-ASA Study Group. Z Gastroenterol. 1995;33:581–4.

    CAS  PubMed  Google Scholar 

  36. Martin FSL, Beck IT, Anderson AH, Williams CN, Saibel F, Barrowman J, Lemire S. Oral 5-ASA versus prednisone in short term treatment of Crohn’s disease: a multicentre controlled trial. Can J Gastroenterol. 1990;4:452–7.

    Google Scholar 

  37. Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: results of a randomized, multicenter trial. Gastroenterology. 1999;116:521–6.

    Article  CAS  PubMed  Google Scholar 

  38. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease: evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990;98:811–8.

    Article  CAS  PubMed  Google Scholar 

  39. Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1992;102:1647–53.

    CAS  PubMed  Google Scholar 

  40. Sparberg M, Kirsner JB. Long-term corticosteroid therapy for regional enteritis: an analysis of 58 courses in 54 patients. Am J Digest Dis. 1966;11:865–80.

    Article  CAS  PubMed  Google Scholar 

  41. Jones JH, Lennard-Jones JE. Corticosteroids and corticotrophin in the treatment of Crohn’s disease. Gut. 1966;7:181–7.

    Article  CAS  PubMed  Google Scholar 

  42. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–5.

    Article  CAS  PubMed  Google Scholar 

  43. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease: the Global Budesonide Study Group. Gut. 1997;41:209–14.

    Article  CAS  PubMed  Google Scholar 

  44. Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–483 (quiz 464, 484).

    Google Scholar 

  45. Castro M, Rossi L, Papadatou B, et al. Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease. J Pediatr Gastroenterol Nutr. 2007;44:423–6.

    Article  CAS  PubMed  Google Scholar 

  46. Annese V, Latiano A, Rossi L, et al. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients: a pilot uncontrolled study. Am J Gastroenterol. 2005;100:1370–5.

    Article  CAS  PubMed  Google Scholar 

  47. Gill AM, Otaki AT, Daly JR, et al. Oral betamethasone 17-valerate in chronic ulcerative colitis and Crohn’s disease. BMJ. 1965;2:29–31.

    Article  CAS  PubMed  Google Scholar 

  48. Smith RC, Rhodes J, Heatley RV, et al. Low dose steroids and clinical relapse in Crohn’s disease: a controlled trial. Gut. 1978;19:606–10.

    Article  CAS  PubMed  Google Scholar 

  49. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2003:CD000301.

  50. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med. 1995;123:132–42.

    Article  CAS  PubMed  Google Scholar 

  51. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev. 2000:CD000545.

  52. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000:CD000067.

  53. Edsbacker S, Andersson P, Lindberg C, et al. Liver metabolism of budesonide in rat, mouse, and man: comparative aspects. Drug Metab Dispos. 1987;15:403–11.

    CAS  PubMed  Google Scholar 

  54. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn’s disease: Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994;331:836–41.

    Article  CAS  PubMed  Google Scholar 

  55. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn’s disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002;97:1748–54.

    Article  CAS  PubMed  Google Scholar 

  56. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:590–599 (quiz 600).

    Google Scholar 

  57. Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn’s disease: the Israeli Budesonide Study Group. Gastroenterology. 1998;115:835–40.

    Article  CAS  PubMed  Google Scholar 

  58. Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn’s disease: German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol. 1996;8:905–9.

    CAS  PubMed  Google Scholar 

  59. van Ierssel GJ, van der Sluys Veer A, Verspaget HW, et al. Contribution of plasma cortisol to corticosteroid-suppressed peripheral blood natural killer cell activity in Crohn’s disease. Immunopharmacology. 1995;29:11–7.

    Google Scholar 

  60. Escher JC. European Collaborative Research Group on Budesonide in Paediatric IBD: budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol. 2004;16:47–54.

    Article  CAS  PubMed  Google Scholar 

  61. D’Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease. Aliment Pharmacol Ther. 1998;12:419–24.

    Article  PubMed  Google Scholar 

  62. Tursi A, Giorgetti GM, Brandimarte G, et al. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn’s disease: an open-label, budesonide-controlled, randomized study. Med Sci Monitor Int Med J Exp Clin Res. 2006;12:PI29–32.

    Google Scholar 

  63. Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008:CD000296.

  64. Sherlock ME, Seow CH, Steinhart AH, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010:CD007698.

  65. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn’s disease: International Budesonide-Mesalamine Study Group. N Engl J Med. 1998;339:370–4.

    Article  CAS  PubMed  Google Scholar 

  66. Kane SV, Schoenfeld P, Sandborn WJ, et al. The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther. 2002;16:1509–17.

    Article  CAS  PubMed  Google Scholar 

  67. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn’s disease. Inflamm Bowel Dis. 2009;15:375–82.

    Article  PubMed  Google Scholar 

  68. Lichtenstein GR, Bengtsson B, Hapten-White L, et al. Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis. Aliment Pharmacol Ther. 2009;29:643–53.

    Article  CAS  PubMed  Google Scholar 

  69. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996;110:45–51.

    Article  CAS  PubMed  Google Scholar 

  70. Lofberg R, Danielsson A, Suhr O, et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology. 1996;110:1713–8.

    Article  CAS  PubMed  Google Scholar 

  71. Gross V, Andus T, Ecker KW, et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease: the Budesonide Study Group. Gut. 1998;42:493–6.

    Article  CAS  PubMed  Google Scholar 

  72. Ferguson A, Campieri M, Doe W, et al. Oral budesonide as maintenance therapy in Crohn’s disease: results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther. 1998;12:175–83.

    Article  CAS  PubMed  Google Scholar 

  73. Hanauer S, Sandborn WJ, Persson A, et al. Budesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005;21:363–71.

    Article  CAS  PubMed  Google Scholar 

  74. Papi C, Luchetti R, Gili L, et al. Budesonide in the treatment of Crohn’s disease: a meta-analysis. Aliment Pharmacol Ther. 2000;14:1419–28.

    Article  CAS  PubMed  Google Scholar 

  75. Ewe K, Bottger T, Buhr HJ, et al. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn’s disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. Eur J Gastroenterol Hepatol. 1999;11:277–82.

    Article  CAS  PubMed  Google Scholar 

  76. Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease: the IOIBD Budesonide Study Group. Gastroenterology. 1999;116:294–300.

    Article  CAS  PubMed  Google Scholar 

  77. Cortot A, Colombel JF, Rutgeerts P, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn’s disease. Gut. 2001;48:186–90.

    Article  CAS  PubMed  Google Scholar 

  78. Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3:113–21.

    Article  CAS  PubMed  Google Scholar 

  79. Fiorino G, Fries W, De La Rue SA, et al. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. Curr Med Chem. 2010;17:1851–7.

    Article  CAS  PubMed  Google Scholar 

  80. Brunner M, Ziegler S, Di Stefano AF, et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol. 2006;61:31–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. D’Haens GR, Kovacs A, Vergauwe P, et al. Clinical trial: preliminary efficacy and safety study of a new budesonide-MMX(R) 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis. 2010;4:153–60.

    Article  PubMed  Google Scholar 

  82. Foe K, Cutler DJ, Brown KF, et al. Metabolism kinetics of beclomethasone propionate esters in human lung homogenates. Pharm Res. 2000;17:1007–12.

    Article  CAS  PubMed  Google Scholar 

  83. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329–39.

    Article  CAS  PubMed  Google Scholar 

  84. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2010:CD000545.

  85. Willoughby JM, Beckett J, Kumar PJ, et al. Controlled trial of azathioprine in Crohn’s disease. Lancet. 1971;2:944–7.

    Article  CAS  PubMed  Google Scholar 

  86. Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology. 1993;105:367–72.

    CAS  PubMed  Google Scholar 

  87. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med. 1980;302:981–7.

    Article  CAS  PubMed  Google Scholar 

  88. Klein M, Binder HJ, Mitchell M, et al. Treatment of Crohn’s disease with azathioprine: a controlled evaluation. Gastroenterology. 1974;66:916–22.

    CAS  PubMed  Google Scholar 

  89. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn’s disease: a double-blind, randomized Israeli multicenter trial. Am J Gastroenterol. 1997;92:2203–9.

    CAS  PubMed  Google Scholar 

  90. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut. 1995;37:674–8.

    Article  CAS  PubMed  Google Scholar 

  91. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.

    Article  CAS  PubMed  Google Scholar 

  92. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.

    Article  CAS  PubMed  Google Scholar 

  93. Mayberry JF, Lobo A, Ford AC, et al. NICE clinical guideline (CG152): the management of Crohn’s disease in adults, children and young people. Aliment Pharmacol Ther. 2013;37:195–203.

    Article  CAS  PubMed  Google Scholar 

Download references

Grant support

This research was supported by grants from the Swiss National Science Foundation (SNSF) to SRV (Grant No. 320000-114009/3 and 32473B_135694/1), to GR (Grant No. 310030-120312), to AS (Grant No. 32003B_135665/1), to MS (Grant No. 314730-146204), to the Swiss IBD Cohort (Grant No. 3347CO-108792), and the Center for Integrative Human Physiology of the University of Zurich to SRV, MS and GR.

Disclaimers for all authors

SR Vavricka, AM Schoepfer, M Scharl and G Rogler have no conflicts of interest or financial interests related to the manuscript to disclose.

Writing assistance

None.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Stadtspital Triemli Hospital, Zurich, 8063, Switzerland

    Stephan R. Vavricka

  2. Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland

    Stephan R. Vavricka, Michael Scharl & Gerhard Rogler

  3. Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

    Alain M. Schoepfer

Authors
  1. Stephan R. Vavricka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alain M. Schoepfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Scharl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gerhard Rogler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephan R. Vavricka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vavricka, S.R., Schoepfer, A.M., Scharl, M. et al. Steroid Use in Crohn’s Disease. Drugs 74, 313–324 (2014). https://doi.org/10.1007/s40265-014-0183-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0183-y

Keywords

Search

Navigation